[Perspective for personalized medicine for diabetes].
Kadowaki
Takashi
T
Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo.
D052242:Adiponectin; D000818:Animals; D001565:Benzoates / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000235:genetics / Q000628:therapy*; D004992:Ethics, Medical; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D005791:Patient Care / Q000639:trends*; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D011506:Proteins / Q000235:genetics; D018160:Receptors, Cytoplasmic and Nuclear / Q000037:antagonists & inhibitors / Q000235:genetics; D014157:Transcription Factors / Q000037:antagonists & inhibitors / Q000235:genetics
D052242:Adiponectin; D001565:Benzoates; D001713:Biphenyl Compounds; D036341:Intercellular Signaling Peptides and Proteins; D011506:Proteins; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; C438269:diazepinylbenzoic acid